A Role for TLR2 in Regulating Immune Surveillance in Pancreatic Ductal Adenocarcinoma
TLR2 在调节胰腺导管腺癌免疫监视中的作用
基本信息
- 批准号:10668252
- 负责人:
- 金额:$ 4.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAmyloidApoptosisBiologyBone MarrowBone Marrow Cell TransplantationCD8-Positive T-LymphocytesCancer EtiologyCell DeathCell physiologyCellsCessation of lifeCommunicationComplementCytometryDataDevelopmentDiseaseEducational process of instructingEndothelial CellsEnvironmentEpithelial CellsFlow CytometryGeneticHarvestHematopoieticHepatocyteImmuneImmune EvasionImmunologic SurveillanceImmunologicsImmunotherapyImplantInfiltrationInjectionsInstitutionKnock-outKnockout MiceKnowledgeKupffer CellsLiverMalignant NeoplasmsMalignant neoplasm of pancreasMentorsMentorshipMetastatic Neoplasm to the LiverMonitorMusMyelogenousMyeloid CellsMyeloid-derived suppressor cellsNatureOrganOutcomePancreasPancreatic Ductal AdenocarcinomaPathogenesisPathway interactionsPatientsPhenotypePopulationProductivityProteinsPublishingResearchResistanceRoleSerumSerum amyloid A proteinSignal PathwaySignal TransductionSolidSurvival RateT cell infiltrationT cell regulationT-LymphocyteTLR2 geneTestingTimeTrainingTumor BiologyTumor BurdenWild Type MouseWorkcell typechimeric antigen receptor T cellsdesigneffector T cellimmune resistanceimmunoregulationimprovedineffective therapiesintravenous injectionliver functionliver inflammationmortalitymouse modelnew therapeutic targetnovelnovel strategiespancreatic cancer modelpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelreceptorreconstitutiontraffickingtumortumor immunology
项目摘要
ABSTRACT
Immunotherapy has shown remarkable benefit for some patients with solid cancers. However, it has largely been
ineffective for the treatment of pancreatic ductal adenocarcinoma (PDAC). Notably, cancers with liver metastasis
often show decreased responsiveness to immunotherapy and PDAC commonly metastasizes to the liver. Our
lab has previously shown that PDAC triggers liver inflammation during early disease pathogenesis that
subsequently supports metastasis to the liver. However, it remains unclear how the liver might influence
outcomes to immunotherapy. The liver is classically known as an immunoregulatory organ involved in regulating
T cell tolerance. Preliminary data show that serum amyloid A (SAA) proteins released by the liver in the setting
of PDAC development suppress T cell surveillance in mouse models of PDAC such that genetic deletion of SAA
converts PDAC tumors from T cell “poor” to T cell “rich”. SAA are known to signal through toll-like receptor 2
(TLR2) and consistent with this, preliminary data also show that genetic deletion of TLR2 causes T cell infiltration
into PDAC tumors even in the presence of high levels of SAA. This finding implicates the SAA/TLR2 signaling
pathway as a determinant of T cell surveillance in PDAC. However, little is known about how TLR2 regulates T
cells surveillance in cancer. It is the central hypothesis of this proposal that TLR2 signaling causes
sequestration of tumor-specific effector T cells in the liver which then undergo apoptosis, thereby
limiting productive T cell surveillance in PDAC. To test this hypothesis, in Aim One I will define cellular
mechanisms by which TLR2 regulates T cell surveillance in PDAC. In Aim Two, I will determine the impact of
TLR2 on tumor-specific T cell fate and the efficacy of T cell immunotherapy. Altogether, studies in this proposal
will improve our understanding of the role of tumor-extrinsic features in regulating immune resistance in PDAC
with the aim to identify novel strategies for improving the efficacy of immunotherapy. This project will be
sponsored by an established mentor with expertise in cancer immunology and tumor biology. This sponsorship
entails a strong commitment to mentorship at an institution with an exceptional environment for training in cancer
immunology and tumor biology. The project also includes a rigorous graduate training plan to complement
training in scientific research with didactics and training in scientific communication and teaching.
摘要
免疫疗法对一些实体癌患者显示出显着的益处。然而,它在很大程度上
对于胰腺导管腺癌(PDAC)的治疗无效。值得注意的是,伴有肝转移的癌症
通常表现出对免疫治疗的反应性降低,并且PDAC通常转移到肝脏。我们
实验室先前已经表明,PDAC在早期疾病发病过程中触发肝脏炎症,
随后支持转移到肝脏。然而,目前还不清楚肝脏如何影响
免疫治疗的结果。肝脏通常被称为免疫调节器官,参与调节
T细胞耐受性初步数据显示,血清淀粉样蛋白A(SAA)蛋白释放的肝脏在设置
在PDAC小鼠模型中,PDAC发育的基因缺失抑制T细胞监视,
将PDAC肿瘤从T细胞“贫乏”转化为T细胞“丰富”。已知SAA通过Toll样受体2发出信号
与此一致,初步数据也表明TLR 2的遗传缺失导致T细胞浸润,
甚至在存在高水平SAA的情况下也能进入PDAC肿瘤。这一发现暗示了SAA/TLR 2信号转导
作为PDAC中T细胞监视的决定因素。然而,关于TLR 2如何调节T细胞,
癌症中的细胞监测。这一提议的核心假设是TLR 2信号传导导致
将肿瘤特异性效应T细胞隔离在肝脏中,然后进行细胞凋亡,从而
限制了PDAC中的生产性T细胞监视。为了验证这一假设,在目标一中,我将定义细胞
TLR 2调节PDAC中T细胞监视的机制。在目标二中,我将确定
TLR 2对肿瘤特异性T细胞命运和T细胞免疫疗法的功效。总的来说,本提案中的研究
将提高我们对肿瘤外在特征在PDAC中调节免疫抵抗的作用的理解
其目的是鉴定用于提高免疫疗法功效的新策略。该项目将
由一位在癌症免疫学和肿瘤生物学方面具有专长的知名导师赞助。此次赞助
需要在一个具有特殊癌症培训环境的机构中坚定地致力于指导
免疫学和肿瘤生物学。该项目还包括一个严格的研究生培训计划,以补充
教学法科学研究培训以及科学交流和教学培训。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacqueline Plesset其他文献
Jacqueline Plesset的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacqueline Plesset', 18)}}的其他基金
A Role for TLR2 in Regulating Immune Surveillance in Pancreatic Ductal Adenocarcinoma
TLR2 在调节胰腺导管腺癌免疫监视中的作用
- 批准号:
10464921 - 财政年份:2022
- 资助金额:
$ 4.77万 - 项目类别:
相似国自然基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
- 批准号:
- 批准年份:2020
- 资助金额:63 万元
- 项目类别:面上项目
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
- 批准号:81870666
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
- 批准号:81601123
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
- 批准号:30971012
- 批准年份:2009
- 资助金额:35.0 万元
- 项目类别:面上项目
抗阿兹海默病Beta-Amyloid寡聚物单链可变区抗体的筛选及其动物试验
- 批准号:30570622
- 批准年份:2005
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
The Role of Apoptosis Repressor with Caspase Recruitment Domain (ARC) in Amyloid-Induced Beta-cell Apoptosis
凋亡抑制蛋白与半胱天冬酶募集结构域 (ARC) 在淀粉样蛋白诱导的 β 细胞凋亡中的作用
- 批准号:
9048561 - 财政年份:2015
- 资助金额:
$ 4.77万 - 项目类别:
The Role of Apoptosis Repressor with Caspase Recruitment Domain (ARC) in Amyloid-Induced Beta-cell Apoptosis
凋亡抑制蛋白与半胱天冬酶募集结构域 (ARC) 在淀粉样蛋白诱导的 β 细胞凋亡中的作用
- 批准号:
9182815 - 财政年份:2015
- 资助金额:
$ 4.77万 - 项目类别:
Anti-apoptotic effect of SERM on the amyloid-β-induced apoptosis in PC12
SERM对淀粉样蛋白-β诱导的PC12细胞凋亡的抗凋亡作用
- 批准号:
18591822 - 财政年份:2006
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of methods to inhibit apoptosis induced by intracellular amyloid β-protein in Alzheimer's disease
开发抑制阿尔茨海默病细胞内β淀粉样蛋白诱导的细胞凋亡的方法
- 批准号:
18590948 - 财政年份:2006
- 资助金额:
$ 4.77万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PRESENILINS, APOPTOSIS AND AMYLOID BETA PROTEIN
早老素、细胞凋亡和β淀粉样蛋白
- 批准号:
6497186 - 财政年份:2000
- 资助金额:
$ 4.77万 - 项目类别:
PRESENILINS, APOPTOSIS AND AMYLOID BETA PROTEIN
早老素、细胞凋亡和β淀粉样蛋白
- 批准号:
6627928 - 财政年份:2000
- 资助金额:
$ 4.77万 - 项目类别:
PRESENILINS, APOPTOSIS AND AMYLOID BETA PROTEIN
早老素、细胞凋亡和β淀粉样蛋白
- 批准号:
6052600 - 财政年份:2000
- 资助金额:
$ 4.77万 - 项目类别:
PRESENILINS, APOPTOSIS AND AMYLOID BETA PROTEIN
早老素、细胞凋亡和β淀粉样蛋白
- 批准号:
6349729 - 财政年份:2000
- 资助金额:
$ 4.77万 - 项目类别: